Components of the DEFLUX gel

DEFLUX is a viscous gel consisting of two components: dextranomer (Dx) microspheres and Q-Med's patented NASHA technology for the production of Stabilized Non-Animal Hyaluronic Acid. Both components are made up of polysaccharides–sugar-based molecules. Dextranomer microspheres are formed by cross-linking dextran polymers into porous beads 80–250 μm in diameter.

Both constituents of DEFLUX are biocompatible.^{1, 2} and well tolerated. The physical and chemical characteristics of NASHA™ are very similar to the hyaluronic acid found naturally within the body. In an early study, no adverse reactions were reported following DEFLUX injection into rats and pigs, or following injection into 75 patients with VUR.³ No major changes were observed in histopathological studies of tissues surrounding implanted DEFLUX in rats or pigs.⁴
 

Image: Deflux – dextranomer microspheres in a gel of stabilised non-animal hyaluronic acid  

NASHA technology

Critical steps in the production of Q-Med’s patented NASHA technology create an almost ideal material for the treatment of VUR.

• The hyaluronic acid is synthesized by cultured bacteria (i.e. a non-animal source).
• The hyaluronic acid undergoes a stabilization process, to form a gel with increased viscosity and stability.

Dextranomer

Dextranomer consists of dextran polymers (chains of glucose molecules), cross-linked through hydroxyl groups to form microspheres. The microspheres used in DEFLUX have a diameter of between 80 and 250 μm. This large size minimizes any risk of the microspheres migrating from the site of injection to other areas of the body.